NCT01014247View on ClinicalTrials.gov

Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation

PHASE1CompletedINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions

QTc EvaluationElectrocardiography

Interventions

DRUG

Avelox (Moxifloxacin, BAY12-8039)

Single dose of 400 mg

DRUG

Placebo

Single dose of matching tablet

Trial Locations (6)

3004

Melbourne

35392

Giessen

119228

Singapore

168752

Singapore

01307

Dresden

W12 0HS

London

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY

NCT01014247 - Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation | Biotech Hunter | Biotech Hunter